News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellectis: An Innovative Anti-cancer Approach



12/18/2012 9:24:11 AM

PARIS--(BUSINESS WIRE)--Regulatory News: Cellectis (Alternext: ALCLS), the genome engineering specialist, announces today the signing of a broad collaboration agreement with the University College of London (UCL) on the development of a therapy program to fight leukemia.

Read at BioSpace.com


comments powered by Disqus
Cellectis
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES